Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil

• Main Authors: Edgardo Kaplinsky (Author), Gordon Mallarkey (Author)
• Formato: Livro
• Publicado em: BioExcel Publishing Ltd, 2018-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...